Form 4: CalciMedica CMO Boosts Stake with Share Purchases
Insider Transaction Report
CalciMedica's Chief Medical Officer, Sudarshan Hebbar, acquired additional common stock in open market transactions.
Summary
- Sudarshan Hebbar, Chief Medical Officer of CalciMedica, Inc. (CALC), purchased a total of 5,976 shares of common stock through two separate transactions.
- On August 14, 2025, 1,584 shares were acquired at a weighted average price of $2.585 per share, with prices ranging from $2.57 to $2.61.
- On August 15, 2025, an additional 4,392 shares were purchased at a weighted average price of $2.793 per share, with prices ranging from $2.70 to $2.85.
- Following these transactions, Sudarshan Hebbar directly beneficially owns 51,976 shares of CalciMedica common stock.
Sentiment
Score: 8
Explanation: The sentiment is positive due to significant insider buying by a key executive, indicating strong internal confidence in the company's prospects.
Positives
- The Chief Medical Officer's open market purchases demonstrate confidence in the company's future prospects and valuation.
- The acquisition of shares at varying price points indicates a belief in the stock's value across a range.
Future Outlook
NA
Industry Context
This filing reflects an individual insider's transaction and does not provide broader industry context or trends. However, insider buying can be a positive signal within the biotechnology sector, indicating management's belief in upcoming milestones or product development.
Stakeholder Impact
- Shareholders may view these insider purchases as a positive indicator, potentially increasing investor confidence and demand for the stock.
- Employees might interpret the CMO's investment as a sign of stability and belief in the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 08/14/2025 | Date of first common stock acquisition by Sudarshan Hebbar. |
| 08/15/2025 | Date of second common stock acquisition by Sudarshan Hebbar. |
| 08/18/2025 | Date the Form 4 filing was signed and submitted. |
Recommendation
buyThe Chief Medical Officer's decision to purchase a substantial number of shares in the open market signals strong conviction in CalciMedica's future. Insider buying, especially from a key executive with deep operational knowledge, often precedes positive developments or reflects a belief that the stock is undervalued. This action suggests a favorable outlook from within the company, making it a compelling 'buy' signal for investors.
Keywords
CalciMedica, CALC, Insider Buying, Form 4, Stock Purchase, Chief Medical Officer, Sudarshan Hebbar, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.